You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
友芝友生物-B(02496.HK)與正大天晴就M701訂立許可與合作協議

格隆匯10月8日丨友芝友生物-B(02496.HK)發佈公吿,2024年10月7日,公司(作為許可人)與中國生物製藥(01177.HK)附屬公司正大天晴藥業集團股份有限公司(“正大天晴”,作為被許可人)訂立許可與合作協議,據此,公司授予正大天晴在許可地區及許可領域內對許可產品進行開發、註冊、生產及商業化的獨家、可分許可的許可。

根據許可與合作協議,公司授予正大天晴在許可地區及許可領域內對許可產品進行開發、註冊、生產及商業化的獨家、可分許可的許可。根據研發進展情況,正大天晴將就許可產品向公司支付最高合共人民幣3.15億元的首付款及額外開發里程碑付款。

雙特異性抗體M701是公司自主研發的生物一類新藥,擬被開發用於腫瘤引起的惡性胸水和惡性腹水的治療,目前處於臨牀試驗III期,是國內首個自主開發並進入臨牀試驗階段的CD3/EpCAM雙特異性抗體。M701可同時靶向腫瘤細胞靶點 EpCAM和免疫T細胞活化靶點CD3,通過雙靶結合橋連腫瘤細胞和免疫T細胞,從而激活T細胞對腫瘤細胞進行殺傷。因此腹腔╱胸腔灌注M701可激活免疫細胞靶向清除或抑制腹腔╱胸腔中的腫瘤細胞。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account